- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00901160
Thromboelastography (TEG®) and Platelet Function in Patients on Anti-platelet Agents
April 7, 2015 updated by: McMaster University
Pilot Study for the Prediction of Post-operative Thrombotic and Bleeding Complications in Non-cardiac Surgery Using Thromboelastography (TEG®) and Platelet Mapping Assay (PMA™) in Patients on Anti-platelet Agents
Can a post-operative analysis using a simple blood test (Thromboelastography(TEG®)) and Platelet Mapping Assay (PMA™) be able to detect the occurence of clotting or bleeding complications in patients on blood thinning (anti-platelet) agents?
Study Overview
Detailed Description
Two hundred patients coming for surgery who are taking anti-platelet medications will be enrolled in this study as a pilot, to determine the feasibility for a larger study.
A simple blood test for clotting function will be done after surgery.
Patients will be assessed daily during their hospital stay to determine if they have any clotting or bleeding complications.
For analysis, groups will be divided into normal and increased or decreased ability to make a blood clot based on the TEG® and PMA™ test done.
Complications will be recorded for each group and analyzed to determine if there is any difference between groups.
Study Type
Observational
Enrollment (Actual)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Hamilton Health Sciences
-
Toronto, Ontario, Canada, M5G 2C4
- University Health Network
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients who are having non-ambulatory, non-cardiac, elective surgery
Description
Inclusion Criteria:
- patients on aspirin and/or clopidogrel for at least 10 days, having non-ambulatory, non-cardiac, elective surgery
Exclusion Criteria:
- anemia (Hb < 100) or thrombocytopenia (platelet count < 80), having any known clotting abnormalities
- family history of clotting abnormalities
- concurrently on NSAIDs, warfarin therapy or other treatments affecting platelet function
- renal impairment (Cr > 110 mg for females or Cr > 125 mg) or INR > 1.2
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Surgical patients
Blood will be taken from patients who are on anti-platelet medication and are having surgery that requires an overnight stay.
This is a pilot study to see if Thromboelastography® and Platelet Mapping Assay™ will be able to predict if a patient is at risk for a bleeding or a clotting problem after surgery.
|
Blood will be taken from patients shortly after surgery in the recovery room in order to perform Thromboelastography® and Platelet Mapping Assay™ tests.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Patients undergoing non-cardiac (non-ambulatory) surgery and are on anti-platelet agents, is hyper or hypocoagulability based on TEG® and PMA™ associated with increased risk of thrombotic and bleeding complications.
Time Frame: 1 month
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Is hypercoagulability based on TEG®(MA) and PMA™ associated with increased risk of the following events post-op: MI, stroke, PE, DVT, death?
Time Frame: 1 month
|
1 month
|
Is hypo-coagulation status associated with lower levels of nadir and discharge hemoglobin/hematocrit and increased transfusion?
Time Frame: 1 month
|
1 month
|
Is coagulation status associated with hospital length of stay?
Time Frame: 1 month
|
1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Summer Syed, M.D., Hamilton Health Sciences Corporation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2008
Primary Completion (Actual)
March 1, 2009
Study Completion (Actual)
June 1, 2011
Study Registration Dates
First Submitted
May 11, 2009
First Submitted That Met QC Criteria
May 12, 2009
First Posted (Estimate)
May 13, 2009
Study Record Updates
Last Update Posted (Estimate)
April 8, 2015
Last Update Submitted That Met QC Criteria
April 7, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 07-468
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Clotting
-
Medical College of WisconsinTerminatedTransgenderism | Clotting DisorderUnited States
-
Hannover Medical SchoolTerminatedClotting Disorder Due to Plasma Exchange Therapy | Humoral Rejection After Kidney TransplantationGermany
-
Ullevaal University HospitalRikshospitalet University HospitalCompletedExtracorporeal Clotting During HemodialysisNorway
-
Sciema UGPerosphere Technologies IncRecruiting
-
Perosphere Pharmaceuticals Inc, a wholly owned...Quintiles, Inc.Completed
-
Robert PendletonUniversity of LouisvilleCompleted
-
Medical University of GrazCompletedDrug Toxicity | Platelet Dysfunction | Clotting DisorderAustria
-
Perosphere Pharmaceuticals Inc, a wholly owned...Quintiles, Inc.Completed
-
Medical University InnsbruckCompletedBlood Clotting | Blood Platelet TransfusionAustria, Denmark
Clinical Trials on blood test
-
French National Agency for Research on AIDS and...Completed
-
Pascual Gregori RoigHospital Universitario de la Plana; FUNDACIÓN DAVALOS FLETCHERCompletedHyperbilirubinemia, Neonatal | Anemia Neonatal | Polycythemia SecondarySpain
-
Wingate InstituteTel Aviv UniversityCompleted
-
University Hospital, ToursCompleted
-
Cairo UniversityUnknownClass III Malocclusion | Class II Malocclusion
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Imperial College LondonCompletedHereditary Hemorrhagic Telangiectasia | Pulmonary Arteriovenous MalformationsUnited Kingdom
-
Minovia Therapeutics Ltd.RecruitingMyelodysplastic SyndromesIsrael
-
Centre Hospitalier Universitaire de NīmesRecruitingNeoplasm Metastasis | Colorectal Cancer | Disseminated CancerFrance
-
University Hospital, GenevaHospices Civils de LyonNot yet recruitingAbuse, Child | Protein Disorder, BloodFrance, Switzerland